777pub legit

Stockhead Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Small caps poised for a rebound in 2025, says Shaw and Partners Falling interest rates could boost small cap growth Small caps offer better diversification and strong returns Shaw and Partners' 2024 stock picks have performed exceptionally well, with the investment advice and wealth management firm's 10 emerging company selections up an average of 49%, highlighted by Metro Mining's (ASX:MMI) standout 210% gain. Name Ticker YTD Return 2024 Metro Mining MMI 210% Gentrack GTK 96% FireFly Metals FFM 70% MMA Offshore MRM 65% Austin Engineering ANG 64% Silex SLX 50% AIC Mines A1M -4% Readytech RDY -15% Chrysos C79 -44% Peninsula PEN -50% Looking ahead, Shaw and Partners is even more optimistic about 2025, predicting a strong rebound for ASX small-cap stocks. With several key factors at play, the research firm believes 2025 could be the ideal time to invest in these often-overlooked opportunities. One of the most compelling reasons to invest in small caps is their recent underperformance compared to large caps. Over the past three years, small-cap stocks have lagged behind by 10% per year. This is an unusually large gap, especially when considering historical trends. Shaw and Partners research analysts point out that such underperformance has often been followed by a swift rebound when market conditions improve, particularly when interest rates start to fall. Smaller companies tend to be more reliant on external financing, so when interest rates fall, their borrowing costs decrease, giving them more room to expand. “The relative performance can mean revert quickly given favourable fundamentals,” the wealth management firm explained. “Over the past decade, there have been two periods of RBA interest rate cuts, each case resulting in Australian small cap stocks rising strongly and outperforming large caps.” Another key reason to look at small caps right now is their superior growth potential. Historically, small companies have outpaced large companies in earnings growth, as their smaller size allows them to grow faster from a smaller base. “Equity markets look forward, and consensus estimates forecast stronger EPS growth for small caps relative to large caps as the economy normalises post-Covid,” Shaw and Partners said. Small-cap stocks often have exposure to niche industries, which can lead to faster growth when conditions are right. Diversification and upside Small-cap stocks also provide greater diversification compared to large caps. The biggest stock in the ASX 100, BHP (ASX:BHP) , has a weighting of over 10%, which means its performance can dramatically impact the index. On the other hand, the largest stock in the small-cap index is Life360 (ASX:360) , which makes up just 1.6%. This means small-cap investors can access a broader range of companies across sectors, from technology to consumer products, without being overly exposed to any one company. “This diversification can help investors capture growth across a wider spectrum of the economy,” noted Shaw. Also, the firm said that small-cap managers have consistently delivered strong returns. The “median small-cap manager has outperformed their benchmark across 1, 3, 5, 10, and 15-year timeframes,” Shaw said, largely due to the inefficiencies in the small-cap market, such as lower liquidity and less analyst coverage. This creates opportunities for active managers to generate ‘alpha’ – returns that exceed the market average. Also, current valuations offer attractive entry points, particularly as small caps are trading on a 2-year forward price-to-earnings (P/E) ratio of 16.2, which is below the 17.9 P/E for large caps. Historically, small caps have traded at a premium to large caps, so this discount could represent a solid buying opportunity. Shaw and Partners’ Top 10 small cap ideas for 2025 As 2025 approaches, Shaw and Partners has selected its top 10 small-cap stocks to watch, and provided the following comments for each: Amaero International (ASX:3DA) leads in metal additive manufacturing, targeting aerospace defence, and energy sectors. Leveraging advanced materials and strategic partnerships, it benefits from re-shoring trends and increased defence spending, driving significant growth opportunities. Australian Vanadium (ASX:AVL) is developing an Australian battery industry utilising vanadium flow batteries that will be used for grid-scale storage. The energy transition requires both electricity generation and matched storage to balance the grid. Beforepay Group (ASX:B4P) is now profitable with its core pay advance lending product. B4P is using its AI algorithms for two new businesses that can double revenue by (1) supplying larger/longer personal loans and (2) supplying AI credit risk modules to US financial institutions. Bannerman Energy (ASX:BMN) is developing the Etango Uranium Project in Namibia. Etango is one of only a handful of construction ready uranium projects globally. It is a large (~215Mlb) and long life (~40 years) asset. The uranium price is expected to continue rising due to strong demand coupled with limited supply. Chrysos Corporation's (ASX:C79) proprietary photon assay technology is making mineral assays faster, more accurate and more environmentally friendly. C79 trades on FY25 EV (expected value) revenue multiple of 8.4x and we forecast a 3-year revenue CAGR (compound annual growth rate) of 46%. We see considerable upside as our $7.20 PT (price target) only assumes 265 terminal units vs a current TAM (total addressable market) of 610 units. Humm (ASX:HUM) is a value investment emerging from restructuring and turning to growth. It is trading on a PE (price earnings) of 4x with earnings growth looking solid for FY25. It is Australia’s leading non-bank financial in secured asset lending to SME’s. Metro Mining (ASX:MMI) ships bauxite to China and is trading at just 3.7x PE and 1.5x EV/EBITDA in 2025. Bauxite prices are rising due to strong demand from China at a time of supply disruptions in Guinea, China and an export ban from Indonesia. Santana Minerals (ASX:SMI) is an advanced gold developer. The company is continuing to develop the 100% owned Bendigo-Ophir Gold Project in New Zealand that boasts 2.5Moz in resource. Shaw sees SMI rerate as it rapidly progresses to production whilst simultaneously continuing to explore its sizeable land package. Silex Systems (ASX:SLX) has the potential to be a generational investment, Shaw says. Its technology is "likely to revolutionise the uranium enrichment industry". There are positive catalysts in 2025 as the pilot plant proves up the technology, Cameco exercises its option to increase its stake in the joint venture and the US government provides financial support. Southern Cross Electrical Engineering (ASX:SXE) is a leading national electrical, instrumentation, communications, and maintenance services group. SXE is exposed to the electrification and decarbonisation of the economy. We are attracted to SXE due to the quality of its management and the strength of its industry tailwinds. The views, information, or opinions expressed in this article are solely those of the research firm and do not represent the views of Stockhead. Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article. Originally published as Shaw says 2025 could be the year to feast on ASX small caps and these are its 10 favourites More related stories Stockhead Argentine lithium junior drawing major eyes Pursuit Minerals says its increased resource in Argentina opens the door to significant offtake discussions despite sluggish lithium prices. Read more Stockhead Net zero goals still need hydrogen Heavy transport and displacing fossil fuel-derived hydrogen are some of the key areas where clean hydrogen can shine. Read more

President Joe Biden honored former President Jimmy Carter as “an extraordinary leader, statesman and humanitarian” after the nation's 39th commander-in-chief died on Sunday. “With his compassion and moral clarity, he worked to eradicate disease, forge peace, advance civil rights and human rights, promote free and fair elections, house the homeless, and always advocate for the least among us,” Biden said in a statement. “He saved, lifted, and changed the lives of people all across the globe.” Carter, who died at age 100 , was the longest living former president. Biden said an official state funeral for Carter will be held in Washington D.C. Peanut farmer to President: Jimmy Carter's unprecedented path into politics and beyond Biden was the first sitting senator to endorse Carter when the Democrat ran for president against Gerald Ford in 1976, according to the Carter Library. Almost a half century later, Cater returned the favor when he supported Biden in 2020, calling him a "loyal and dedicated friend." However, Carter was unable to attend Biden’s inauguration – marking the first time the 39th president missed a presidential-handoff ceremony since he took the oath of office in 1977. “Over six decades, we had the honor of calling Jimmy Carter a dear friend,” Biden said in the statement. “But, what’s extraordinary about Jimmy Carter, though, is that millions of people throughout America and the world who never met him thought of him as a dear friend as well.” Biden in the statement with First Lady Jill Biden said they cherished Carter’s relationship with his wife Rosalynn , saying it was “the definition of partnership and their humble leadership is the definition of patriotism.” Rosalynn Carter died at the age of 96 in November 2023. While Biden honored his longtime friend in his statement, he also called on Americans to study Jimmy Carter’s life and principles. “And to all of the young people in this nation and for anyone in search of what it means to live a life of purpose and meaning – the good life – study Jimmy Carter, a man of principle, faith, and humility,” Biden said. “He showed that we are great nation because we are a good people – decent and honorable, courageous and compassionate, humble and strong.”

Chronic Refractory Cough Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insights | Genentech, Trevi Therapeutics, Guangdong Hengrui Pharma, Ltd, Bellus Health, Merck 12-12-2024 08:06 PM CET | Health & Medicine Press release from: DelveInsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Refractory Cough pipeline constitutes 4+ key companies continuously working towards developing 4+ Chronic Refractory Cough treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Chronic Refractory Cough Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Refractory Cough Market. The Chronic Refractory Cough Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Chronic Refractory Cough Pipeline Report: https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Chronic Refractory Cough treatment therapies with a considerable amount of success over the years. •Chronic Refractory Cough companies working in the treatment market are Nocion Therapeutics, Genentech, Inc., Trevi Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, Bellus Health Inc, Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., and others, are developing therapies for the Chronic Refractory Cough treatment •Emerging Chronic Refractory Cough therapies in the different phases of clinical trials are- NOC-100, GDC-6599, Haduvio, HRS-2261, BLU-5937, MK-7264 (gefapixant), Orvepitant Maleate, Camlipixant (BLU-5937), AX-8, ADX-629, GDC-6599, and others are expected to have a significant impact on the Chronic Refractory Cough market in the coming years. •In October 2024, Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on developing HaduvioTM (oral nalbuphine ER) for chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), announced the completion of enrollment for its Phase 2a RCC trial ("RIVER") and anticipates releasing topline results in the first quarter of 2025. •In August 2024, Axalbion, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for cough, announced the dosing of the first patient in the second phase of a randomized, placebo-controlled Phase 2 proof-of-concept clinical trial for AX-8, its lead compound. AX-8 is an oral, highly potent, and selective agonist of the transient receptor potential melastatin 8 (TRPM8) ion channel. The company has secured additional funding from both existing and new investors to support the trial and prepare for Phase 3 development. •In March 2024, Nocion Therapeutics, a clinical-stage biopharmaceutical company, announced securing $62 million in Series B funding. The company is developing innovative small molecule, permanently charged sodium channel blockers (CSCBs), known as nocions, which selectively target activated nociceptors to address conditions like cough, itch, and pain. The funds will support the evaluation of their lead program, Taplucanium Dry Powder for Inhalation, in a Phase 2b study for Chronic Cough patients. Chronic Refractory Cough Overview A cough that lasts longer than eight weeks is referred to as chronic, and many individuals with chronic refractory cough have coughs that last considerably longer. Furthermore, the illness is known as chronic refractory cough when the reason of the persistent cough cannot be found or the cough continues even after receiving the best care possible for any related conditions. Get a Free Sample PDF Report to know more about Chronic Refractory Cough Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/chronic-refractory-cough-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Chronic Refractory Cough Drugs Under Different Phases of Clinical Development Include: •NOC-100: Nocion Therapeutics •GDC-6599: Genentech, Inc. •Haduvio: Trevi Therapeutics •HRS-2261: Guangdong Hengrui Pharmaceutical Co., Ltd •BLU-5937: Bellus Health Inc •MK-7264 (gefapixant): Merck & Co/Kyorin Pharmaceuticals •Orvepitant Maleate: NeRRe Therapeutics •Camlipixant (BLU-5937): Bellus Health/GSK •AX-8: Axalbion •ADX-629: Aldeyra Therapeutics •GDC-6599: Genentech, Inc. Route of Administration Chronic Refractory Cough pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as •Oral •Intravenous •Subcutaneous •Parenteral •Topical Molecule Type Products have been categorized under various Molecule types such as •Recombinant fusion proteins •Small molecule •Monoclonal antibody •Peptide •Polymer •Gene therapy Chronic Refractory Cough Pipeline Therapeutics Assessment •Chronic Refractory Cough Assessment by Product Type •Chronic Refractory Cough By Stage and Product Type •Chronic Refractory Cough Assessment by Route of Administration •Chronic Refractory Cough By Stage and Route of Administration •Chronic Refractory Cough Assessment by Molecule Type •Chronic Refractory Cough by Stage and Molecule Type DelveInsight's Chronic Refractory Cough Report 4+ covers around products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Chronic Refractory Cough product details are provided in the report. Download the Chronic Refractory Cough pipeline report to learn more about the emerging Chronic Refractory Cough therapies https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Chronic Refractory Cough Therapeutics Market include: Key companies developing therapies for Chronic Refractory Cough are - Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, Shionogi, Axalbion, Aldeyra Therapeutics and others Chronic Refractory Cough Pipeline Analysis: The Chronic Refractory Cough pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Refractory Cough with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Refractory Cough Treatment. •Chronic Refractory Cough key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Chronic Refractory Cough Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Refractory Cough market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Chronic Refractory Cough drugs and therapies https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Chronic Refractory Cough Pipeline Market Drivers •Increasing Prevalence of cough, growing demand for treatment for Chronic Refractory Cough are some of the important factors that are fueling the Chronic Refractory Cough Market. Chronic Refractory Cough Pipeline Market Barriers •However, lack of awareness, lack of availability of specific biomarkers that are useful for accurate and timely diagnosis and other factors are creating obstacles in the Chronic Refractory Cough Market growth. Scope of Chronic Refractory Cough Pipeline Drug Insight •Coverage: Global •Key Chronic Refractory Cough Companies: Nocion Therapeutics, Genentech, Inc., Trevi Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, Bellus Health Inc, Merck & Co, Kyorin Pharmaceuticals, NeRRe Therapeutics, Bellus Health, GSK, Axalbion, Aldeyra Therapeutics, Genentech, Inc., and others •Key Chronic Refractory Cough Therapies: NOC-100, GDC-6599, Haduvio, HRS-2261, BLU-5937, MK-7264 (gefapixant), Orvepitant Maleate, Camlipixant (BLU-5937), AX-8, ADX-629, GDC-6599, and others •Chronic Refractory Cough Therapeutic Assessment: Chronic Refractory Cough current marketed and Chronic Refractory Cough emerging therapies •Chronic Refractory Cough Market Dynamics: Chronic Refractory Cough market drivers and Chronic Refractory Cough market barriers Request for Sample PDF Report for Chronic Refractory Cough Pipeline Assessment and clinical trials https://www.delveinsight.com/sample-request/chronic-refractory-cough-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Chronic Refractory Cough Report Introduction 2. Chronic Refractory Cough Executive Summary 3. Chronic Refractory Cough Overview 4. Chronic Refractory Cough- Analytical Perspective In-depth Commercial Assessment 5. Chronic Refractory Cough Pipeline Therapeutics 6. Chronic Refractory Cough Late Stage Products (Phase II/III) 7. Chronic Refractory Cough Mid Stage Products (Phase II) 8. Chronic Refractory Cough Early Stage Products (Phase I) 9. Chronic Refractory Cough Preclinical Stage Products 10. Chronic Refractory Cough Therapeutics Assessment 11. Chronic Refractory Cough Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Chronic Refractory Cough Key Companies 14. Chronic Refractory Cough Key Products 15. Chronic Refractory Cough Unmet Needs 16 . Chronic Refractory Cough Market Drivers and Barriers 17. Chronic Refractory Cough Future Perspectives and Conclusion 18. Chronic Refractory Cough Analyst Views 19. Appendix 20. About DelveInsight Related Reports: Chronic Refractory Cough Market https://www.delveinsight.com/report-store/chronic-refractory-cough-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Chronic Refractory Cough Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Chronic Refractory Cough Epidemiology https://www.delveinsight.com/report-store/chronic-refractory-cough-crc-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Chronic Refractory Cough Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Latest Reports: •Apheresis Market: https://www.delveinsight.com/report-store/apheresis-market •Hydrocephalus Market: https://www.delveinsight.com/report-store/hydrocephalus-market •Hemophilia A Market: https://www.delveinsight.com/report-store/hemophilia-a2030-market •Herpes Simplex Virus Market: https://www.delveinsight.com/report-store/genital-herpes-market •Peripheral Nerve Injuries Market: https://www.delveinsight.com/infographics/peripheral-nerve-injuries-market •Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market •Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market •Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.

New Delhi: Electronics and Computer Software Export Promotion Council (ESC) has batted for further calibration of Design Linked Incentive (DLI) scheme to make it more broad-based and impact-oriented. The industry body has made a strong pitch for incentives to promote R&D and innovation in capital-intensive electronics hardware sector during a recent interaction with Finance Minister Nirmala Sitharaman , a release said on Sunday. ESC has also sought additional income tax reduction for Indian corporates spending over 3 per cent of their turnover to advance R&D and filing patents/designs in India. ET Year-end Special Reads What kept India's stock market investors on toes in 2024? India's car race: How far EVs went in 2024 Investing in 2025: Six wealth management trends to watch out for "In an exclusive interaction with Finance Minister Nirmala Sitharaman and other senior officials of the Ministry of Finance recently, the...export promotion council...said that a well-calibrated incentive system designed to empower industry players could motivate nascent industry units to move in the R&D value chain in cutting-edge technology domains like AI, IoT, telecom, and embedded technologies in sectors like semiconductors, consumer electronics, and defence equipment," according to a release by ESC. Implicit in ESC's wish list is the demand for an additional 5 per cent Income Tax reduction for Indian corporates spending over three per cent of their turnover on R&D and filing patents/designs in India, it said adding this aligns with the national goal of fostering innovation, self-reliance, and global competitiveness. "By introducing tax reduction, India can create a compelling incentive for companies to prioritise R&D, leading to technological advancements, the creation of intellectual property, and a reduction in dependence on imports," Sandeep Narula, Chairman, Global Outreach, ESC said. ESC has also pitched for further calibration of the Design Linked Incentive (DLI) Scheme to make it more broad-based and impact-oriented. Artificial Intelligence(AI) Java Programming with ChatGPT: Learn using Generative AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Basics of Generative AI: Unveiling Tomorrows Innovations By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Generative AI for Dynamic Java Web Applications with ChatGPT By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Mastering C++ Fundamentals with Generative AI: A Hands-On By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Master in Python Language Quickly Using the ChatGPT Open AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Performance Marketing for eCommerce Brands By - Zafer Mukeri, Founder- Inara Marketers View Program Office Productivity Zero to Hero in Microsoft Excel: Complete Excel guide 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance A2Z Of Money By - elearnmarkets, Financial Education by StockEdge View Program Marketing Modern Marketing Masterclass by Seth Godin By - Seth Godin, Former dot com Business Executive and Best Selling Author View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Data Science SQL for Data Science along with Data Analytics and Data Visualization By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) AI and Analytics based Business Strategy By - Tanusree De, Managing Director- Accenture Technology Lead, Trustworthy AI Center of Excellence: ATCI View Program Web Development A Comprehensive ASP.NET Core MVC 6 Project Guide for 2024 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Artificial Intelligence(AI) AI-Powered Python Mastery with Tabnine: Boost Your Coding Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Office Productivity Mastering Microsoft Office: Word, Excel, PowerPoint, and 365 By - Metla Sudha Sekhar, IT Specialist and Developer View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Office Productivity Mastering Google Sheets: Unleash the Power of Excel and Advance Analysis By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend to Backend Excellence By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy i.e Lets Crack the Billionaire Code By - CA Rahul Gupta, CA with 10+ years of experience and Accounting Educator View Program Data Science SQL Server Bootcamp 2024: Transform from Beginner to Pro By - Metla Sudha Sekhar, IT Specialist and Developer View Program The suggestions include extending the scheme's duration for an additional 10 years, until January 1, 2035. "Given the long gestation period and complexity involved in electronics and semiconductor design, sustained support over the next decade is critical to fostering innovation, building intellectual property, and reducing reliance on imports," it said. ESC is of the view that a long-term commitment will offer necessary stability and confidence for companies to undertake high-risk, high-reward R&D projects. "Coupled with this, there should be a provision for the rollover of unutilised funds from the current allocation to subsequent years under the extended scheme. This will ensure optimal utilisation of resources, facilitate continuous support for ongoing projects, and maximise the impact of the scheme without leaving allocated budgets underutilised," the release said. Gurmeet Singh, Executive Director, ESC called for additional funding to the tune of USD 20 billion under the DLI scheme to meet the rising demand for R&D in emerging quantum technologies like AI and internet products. ESC has also sought a 10-year Tax Holiday on sales of products with Intellectual Property (IP) such as patents and designs, developed through in-house R&D efforts. This, it said, would incentivise companies, particularly those not utilising the Design Linked Incentive (DLI) Scheme, to invest in the creation of innovative products and technologies. "By providing tax relief on revenues generated from these IP-driven products, the government can encourage the development of proprietary technologies, foster innovation, and reduce the reliance on foreign patents or designs," according to ESC. The industry body noted that the current level of R&D in India's electronics sector "remains relatively modest" with "limited investments compared to global leaders". "While India's electronics market is significant, valued at USD 155 billion in 2022 and expected to grow to USD 300 billion by 2025- 26, its R&D expenditure in the sector is far behind its competitors. Although India's investment in research and development has been continuously increasing over the years and more than doubled in the last 10 years ... However, the country's expenditure as a percentage of GDP remained between 0.6-0.7 per cent as against Chinaas 2.4 per cent, USA 3.5 per cent and Israel 5.4 per cent," ESC release said. Nominations for ET MSME Awards are now open. The last day to apply is December 31, 2024. Click here to submit your entry for any one or more of the 22 categories and stand a chance to win a prestigious award. (You can now subscribe to our Economic Times WhatsApp channel )

RIVERHEAD, N.Y. (AP) — The New York architect facing murder charges in a string of deaths known as the Gilgo Beach killings was charged on Tuesday in the death of a seventh woman. Rex Heuermann pleaded not guilty to killing Valerie Mack, whose remains were first found on Long Island in 2000. Mack, 24, had been working as an escort in Philadelphia and was last seen by her family that year in New Jersey. Some of Mack’s skeletal remains were initially discovered in Manorville, New York; authorities found more of her remains about 50 miles (80 kilometers) west, in Gilgo Beach, more than 10 years later. They were unidentified until genetic testing revealed her identity in 2020. Human hair found with Mack’s remains was sent for testing earlier this year and found to be a likely match with the genetic profile of Heuermann’s daughter, prosecutors said in court papers. His daughter is not accused of any wrongdoing and would have been 3 or 4 years old when Mack died. Heuermann, 61, is charged with killing six other women whose remains were found on Long Island. He has pleaded not guilty to all the charges. “The lives of these women matter,” Suffolk County District Attorney Ray Tierney said at a news conference with Mack's parents and other victims' relatives. “No one understands that more than the families.” Mack's parents didn't speak. Four other victims' relatives gave the Macks roses and hugs and, through an attorney, expressed their sadness and solidarity. “They were, and they are, loved. And they are missed every day by those who knew them and who had a strong bond with them,” said Gloria Allred, who represents the families of Melissa Barthelemy, Maureen Brainard-Barnes, Jessica Taylor and Megan Waterman. Outside of court, Heuermann’s lawyer Michael Brown disputed evidence presented in Mack’s death, saying the DNA technology used to connect her and other victims to Heuermann has never been deemed reliable in a New York case. He also argued that Tierney’s office has yet to produce proof any victims’ DNA was found in Heuermann’s home, including the many weapons and tools seized during recent searches of the property. “There’s something a little weird about these allegations,” Brown said. “Something that doesn’t sit right.” The investigation into the Gilgo Beach killings dates back to 2010, when police searching for a missing woman found 10 sets of human remains in the scrub along a barrier island parkway, prompting fears of a serial killer. Over the years, investigators used DNA analysis and other clues to identify the victims, many of whom were sex workers. Police also began reexamining other unsolved killings of women on Long Island. The case has dragged on through five police commissioners, more than 1,000 tips, and doubts about whether there was a serial killer at all. Heuermann, who lived with his wife and two children in Massapequa Park on Long Island and commuted to a Manhattan architecture office, was arrested on July 13, 2023. At that point, he was charged with murdering Barthelemy, Waterman and Amber Lynn Costello. Earlier this year, he was charged in the deaths of three other women — Brainard-Barnes , Taylor and Sandra Costilla . In a June court filing, prosecutors said they had recovered a file on a hard drive in Heuermann’s basement that he used to “methodically blueprint” his killings — including checklists with tasks for before, during and after, as well as lessons for “next time.” In court papers on Tuesday, prosecutors said the document, which was created the same year as Mack’s murder, includes details that align with her case. For example, it names “Mill Road” — a road near where Mack’s first remains were found — under the heading “DS,” which investigators believe stands for “dump site.” The document also lists “foam drain cleaner” under “Supplies.” Prosecutors say that on Oct. 3, 2000, Heuermann’s phone records appear to show him making two calls to a Long Island plumbing company, and he paid another company the following month to check his mainline drain. In recent searches of Heuermann’s home and office, authorities say they found old magazines and newspapers with articles about the Gilgo Beach killings and investigation that prosecutors believe he kept as “souvenirs” or “mementos.” Among them was a July 29, 2003, copy of the New York Post that included an article about the investigation into Mack and Taylor’s remains. Tierney said Tuesday that evidence points to Heuermann’s home as the scene of the killings — in most cases, when his family was out of town. Heuermann’s estranged wife, Asa Ellerup, said in a statement that she still does not believe her husband was capable of committing the crimes he’s accused of. The couple’s now grown children said in a separate statement they remain “steadfast in observing the legal process play itself out, no matter how long it takes or how difficult it is.” Authorities have still not charged anyone in the deaths of some other people whose remains were found on Long Island. Among them is an unidentified male victim who died in 2006 and likely presented outwardly as a female, and Karen Vergata , whose remains were discovered in 1996 but only identified through new DNA analysis in 2022. ___ Associated Press writer Jennifer Peltz contributed from New York.